Thomson Reuters (Nasdaq/TSX: TRI), a global content and technology company, today unveiled its next major leap forward ...

Legal battle over semaglutide between Novo Nordisk and Indian drugmakers will set precedent for future opportunities and ...

Dr Reddy's Laboratories had received the manufacturing licence for semaglutide in December 2024 and it began production in ...

Legal battle over Novo Nordisk's semaglutide drug in India, with DRL, raises concerns over patent infringement and drug ...

For more than 55 years, Institutional Investor has delivered the news and analysis that investment professionals need to succeed and stay relevant. Our coverage of the global asset management ...

Dr. Reddy’s and OneSource agree not to sell Novo Nordisk’s anti-obesity drug in India amid patent infringement lawsuit.

Novo Nordisk has accused Dr Reddy's and OneSource of importing semaglutide API and using it to make and export formulations.

Delhi High Court bars Dr Reddy's and OneSource from selling semaglutide in India, supporting Novo Nordisk's patent rights as ...

The Delhi High Court proceeded to restrict the two Indian companies from marketing semaglutide, the active ingredient in Novo ...

The court’s intervention comes at a crucial time as Novo Nordisk gears up for the rollout of Wegovy, amid rising global ...